A new in vivo pharmacokinetic recall study involving 114 participants in the Estonian Biobank has provided the first clinical ...

We thank the patient and his family for their participation in this study; all the persons involved in the rapid manufacturing and evaluation of k-abe, including Kamila Wlodarczyk, Nicholas Tougas, ...

Liver fibrosis is a progressive and potentially reversible condition that results from chronic liver damage, which can be caused by a variety of factors, including metabolic dysfunction-associated ...

N4 Pharma plc has successfully completed the first in vivo study of orally delivered Nuvec using its lead program N4 101, an orally administered anti-inflammatory treatment for inflammatory bowel ...